E138K and M184I mutations in HIV-1 reverse transcriptase coemerge as a result of APOBEC3 editing in the absence of drug exposure

AIDS

Volumn 26, Issue 13, 2012, Pages 1619-1624

  Fourati, Slim ^a,b,c   Malet, Isabelle ^a,b,c   Lambert, Sidonie ^a,b,c   Soulie, Cathia ^a,b,c   Wirden, Marc ^a,b,c   Flandre, Philippe ^a,b   Fofana, Djeneba B ^a,b,c   Sayon, Sophie ^b,c   Simon, Anne ^a,b,c   Katlama, Christine ^a,b,c   Calvez, Vincent ^a,b,c   Marcelin, Anne Geneviève ^a,b,c  

^a SORBONNE UNIVERSITÉ   (France)

^b INSERM   (France)

^c ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

Author keywords

APOBEC3; resistance associated mutations; reverse transcriptase; rilpivirine; viral diversity

Indexed keywords

ANTIRETROVIRUS AGENT; APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3; APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3F; EMTRICITABINE PLUS RILPIVIRINE PLUS TENOFOVIR DISOPROXIL; ETRAVIRINE; RILPIVIRINE; RNA DIRECTED DNA POLYMERASE; UNCLASSIFIED DRUG;

ARTICLE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROVIRUS; RNA EDITING; VIRUS MUTANT; VIRUS REPLICATION;

ADENINE; ANTI-HIV AGENTS; CYTOSINE DEAMINASE; DNA MUTATIONAL ANALYSIS; DRUG RESISTANCE, VIRAL; FEMALE; GLUTAMIC ACID; HIV REVERSE TRANSCRIPTASE; HIV-1; HUMANS; ISOLEUCINE; LYSINE; MALE; METHIONINE; MUTATION; NITRILES; ORGANOPHOSPHONATES; PYRIDAZINES; PYRIMIDINES; TREATMENT FAILURE; VIRUS REPLICATION;

EID: 84865526711     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e3283560703     Document Type: Article

References (26)

1. Mansky LM, Temin HM. Lower in vivo mutation rate of human immunodeficiency virus type 1 than that predicted from the fidelity of purified reverse transcriptase. J Virol 1995; 69:5087-5094.
2. Moutouh L, Corbeil J, Richman DD. Recombination leads to the rapid emergence of HIV-1 dually resistant mutants under selective drug pressure. Proc Natl Acad Sci USA 1996; 93:6106-6111. (Pubitemid 26190811)
3. Duffy S, Shackelton LA, Holmes EC. Rates of evolutionary change in viruses: patterns and determinants. Nat Rev Genet 2008; 9:267-276. (Pubitemid 351399833)
4. Simon V, Zennou V, Murray D, Huang Y, Ho DD, Bieniasz PD. Natural variation in Vif: differential impact on APOBEC3G/3F and a potential role in HIV-1 diversification. PLoS Pathog 2005; 1:e6.
5. Mulder LC, Harari A, Simon V. Cytidine deamination induced HIV-1 drug resistance. Proc Natl Acad Sci USA 2008; 105:5501-5506. (Pubitemid 351753892)
6. Hache G, Mansky LM, Harris RS. Human APOBEC3 proteins, retrovirus restriction, and HIV drug resistance. AIDS Rev 2006; 8:148-157. (Pubitemid 44614032)
7. Albin JS, Harris RS.Interactions of host APOBEC3 restriction factors with HIV-1 in vivo: implications for therapeutics. Expert Rev Mol Med 2010; 12:e4.
8. Kim EY, Bhattacharya T, Kunstman K, Swantek P, Koning FA, Malim MH, et al. Human APOBEC3G-mediated editing can promote HIV-1 sequence diversification and accelerate adaptation to selective pressure. J Virol 2010; 84:10402-10405.
9. Fourati S, Malet I, Binka M, Boukobza S, Wirden M, Sayon S, et al. Partially active HIV-1 Vif alleles facilitate viral escape from specific antiretrovirals. AIDS 2010; 24:2313-2321.
10. Sadler HA, Stenglein MD, Harris RS, Mansky LM. APOBEC3G contributes to HIV-1 variation through sublethal mutagenesis. J Virol 2010; 84:7396-7404.
11. Goila-Gaur R, Strebel K. HIV-1 Vif, APOBEC, and intrinsic immunity. Retrovirology 2008; 5:51.
12. Pace C, Keller J, Nolan D, James I, Gaudieri S, Moore C, et al. Population level analysis of human immunodeficiency virus type 1 hypermutation and its relationship with APOBEC3G and vif genetic variation. J Virol 2006; 80:9259-9269. (Pubitemid 44359998)
13. Kieffer TL, Kwon P, Nettles RE, Han Y, Ray SC, Siliciano RF. G!A hypermutation in protease and reverse transcriptase regions of human immunodeficiency virus type 1 residing in resting CD4R T cells in vivo. J Virol 2005; 79:1975-1980. (Pubitemid 40459148)
14. Piantadosi A, Humes D, Chohan B, McClelland RS, Overbaugh J. Analysis of the percentage of human immunodeficiency virus type 1 sequences that are hypermutated and markers of disease progression in a longitudinal cohort, including one individual with a partially defective Vif. J Virol 2009; 83:7805-7814.
15. Gandhi SK, Siliciano JD, Bailey JR, Siliciano RF, Blankson JN. Role of APOBEC3G/F-mediated hypermutation in the control of human immunodeficiency virus type 1 in elite suppressors. J Virol 2008; 82:3125-3130. (Pubitemid 351329200)
16. Cohen CJ, Andrade-Villanueva J, Clotet B, Fourie J, Johnson MA, Ruxrungtham K, et al. Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, noninferiority trial. Lancet 2011; 378:229-237.
17. Molina JM, Cahn P, Grinsztejn B, Lazzarin A, Mills A, Saag M, et al. Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial. Lancet 2011; 378:238-246.
18. Boucher CA, Cammack N, Schipper P, Schuurman R, Rouse P, Wainberg MA, et al. High-level resistance to (-) enantiomeric 20-deoxy-30-thiacytidine in vitro is due to one amino acid substitution in the catalytic site of human immunodeficiency virus type 1 reverse transcriptase. Antimicrob Agents Chemother 1993; 37:2231-2234. (Pubitemid 23298217)
19. Keulen W, Back NK, van Wijk A, Boucher CA, Berkhout B. Initial appearance of the 184Ile variant in lamivudine-treated patients is caused by the mutational bias of human immunodeficiency virus type 1 reverse transcriptase. J Virol 1997; 71:3346-3350. (Pubitemid 27121581)
20. Azijn H, Tirry I, Vingerhoets J, de Bethune MP, Kraus G, Boven K, et al. TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1. Antimicrob Agents Chemother 2010; 54:718-727.
21. Asahchop EL, Oliveira M, Wainberg MA, Brenner BG, Moisi D, Toni T, et al. Characterization of the E138K resistance mutation in HIV-1 reverse transcriptase conferring susceptibility to etravirine in B and non-B HIV-1 subtypes. Antimicrob Agents Chemother 2011; 55:600-607.
22. Tambuyzer L, Vingerhoets J,Azijn H,Daems B, Nijs S, deBethune MP, et al. Characterization of genotypic and phenotypic changes in HIV-1-infected patients with virologic failureon an etravirinecontaining regimen in the DUET-1 and DUET-2 clinical studies. AIDS Res Hum Retroviruses 2010; 26:1197-1205.
23. Tambuyzer L, Nijs S, Daems B, Picchio G, Vingerhoets J. Effect of mutations at position E138 in HIV-1 reverse transcriptase on phenotypic susceptibility and virologic response to etravirine. J Acquir Immune Defic Syndr 2011; 58:18-22.
24. Mulder LC, Ooms M, Majdak S, Smedresman J, Linscheid C, Harari A, et al. Moderate influence of human APOBEC3F on HIV-1 replication in primary lymphocytes. J Virol 2010; 84:9613-9617.
25. O'Neil PK, Sun G, Yu H, Ron Y, Dougherty JP, Preston BD. Mutational analysis of HIV-1 long terminal repeats to explore the relative contribution of reverse transcriptase and RNA polymerase II to viral mutagenesis. J Biol Chem 2002; 277:38053-38061. (Pubitemid 35154657)
26. Gourraud PA, Karaouni A, Woo JM, Schmidt T, Oksenberg JR, Hecht FM, et al. APOBEC3H haplotypes and HIV-1 pro-viral vif DNA sequence diversity in early untreated human immunodeficiency virus-1 infection. Hum Immunol 2011; 72:207-212.